Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
The latest news, research, and perspectives in myeloproliferative neoplasms (MPNs). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Advertisement
Prithviraj Bose, MDMeeting News | December 30, 2024
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
Prithviraj Bose, MDMeeting News | December 30, 2024
The expert panel moderated by Dr. Bose looks at noteworthy study work on use of this agent for anemia in myelofibrosis.
Prithviraj Bose, MDMeeting News | December 30, 2024
Empaneled experts describe their investigations of momelotinib in a continued discussion moderated by Prithviraj Bose, MD.
Prithviraj Bose, MDMeeting News | December 30, 2024
The expert panel moderated by Prithviraj Bose, MD, tells which research presented at the Meeting they found most exciting.
Prithviraj Bose, MDMyelofibrosis | December 31, 2024
Esteemed experts provide valuable insights into the evolving myelofibrosis landscape and its implications for patient care.
Prithviraj Bose, MDMyelofibrosis | December 31, 2024
Key takeaways from the top ASH abstracts in the myelofbrosis space.
Advertisement
Prithviraj Bose, MDMyelofibrosis | December 31, 2024
A roundtale discussion starts with a conversation about the myelofibrosis treatment landscape.
Claire Harrison, MD, FRCP, FRCPathMyeloproliferative Neoplasms | December 26, 2024
An expert's insights on the latest advancements in MF treatment presented at the ASH 2024 meeting.
Benjamin Rolles, MDMyeloproliferative Neoplasms | December 26, 2024
There may be a link between obesity and how myeloproliferative neoplasms develop, research shows.
Blood Cancers Today Staff WritersMeeting News | December 24, 2024
Outcomes for patients with AML and MDS who experience relapse after alloHSCT are poor.
Blood Cancers Today Staff WritersMeeting News | December 24, 2024
Overall, fedratinib 400 mg daily was a safe MTD for post-HSCT maintenance therapy for participants with MPN.
John Mascarenhas, MDMeeting News | December 26, 2024
Discussing current clinical trials iand unmet needs in myelofibrosis.
Patrick DalyAcute Myeloid Leukemia | December 20, 2024
Interim results suggest acceptable safety and high efficacy of CPX-351 plus ivosidenib.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
Findings suggest a potential metabolic benefit of pacritinib, warranting further investigation in myelofibrosis.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
The PROMise trial aims to examine the safety and preliminary efficacy of OPN-2853 with ruxolitinib for MF treatment.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
HMA plus venetoclax may achieve higher response rates and improve event-free survival in high-risk MDS.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
In a murine mitochondrial succinate dehydrogenase knockdown model of low-risk MDS luspatercept alleviated anemia.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
Odyssey is an ongoing, open-label, phase 2 study that will assess the benefit of adding luspatercept to momelotinib.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
At ASH 2024, updated results of the RESTORE trial were presented.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
These real-world findings highlight momelotinib as an effective and practical treatment for managing MF in everyday practice
Advertisement
Advertisement
Editorial Board